Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists

BACKGROUND:  Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are present across various tumor types with an estimated overall prevalence of less than 1%. Tropomyosin receptor kinase inhibitors (TRKis) block the constitutively activated tyrosine receptor kinase (TRK) fusion protein produced...

Descripción completa

Detalles Bibliográficos
Autores principales: Klink, Andrew J, Kavati, Abhishek, Gassama, Awa, Kozlek, Tom, Gajra, Ajeet, Antoine, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512741/
https://www.ncbi.nlm.nih.gov/pubmed/36089643
http://dx.doi.org/10.1007/s11523-022-00909-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512741/
https://www.ncbi.nlm.nih.gov/pubmed/36089643
http://dx.doi.org/10.1007/s11523-022-00909-7

Ejemplares similares